THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt about [illegible]

If you have sold or transferred [illegible] **Shenzhen Hepalink Pharmaceutical Group Co., Ltd.,** [illegible]

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

Hepalink

( )

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

2022 WORK REPORT OF THE BOARD OF DIRECTORS
2022 WORK REPORT OF THE SUPERVISORY COMMITTEE
2022 ANNUAL REPORT AND ITS SUMMARY,
H SHARES RESULTS ANNOUNCEMENT,
H SHARES 2022 ANNUAL REPORT, 2022 CORPORATE GOVERNANCE REPORT AND 2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
2022 FINAL FINANCIAL REPORT
2022 PROFIT DISTRIBUTION PROPOSAL
RE-APPOINTMENT OF AUDITORS OF THE COMPANY
ELECTION OF THE SIXTH SESSION OF THE BOARD
REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF THE SIXTH SESSION OF THE BOARD
ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE
PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND CASH FLOW MANAGEMENT USING INTERNAL FUNDS
APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO CERTAIN BANKS FOR 2023
AMENDMENT OF ARTICLES OF ASSOCIATION
AND
NOTICE OF THE 2022 ANNUAL GENERAL MEETING

A [illegible] 3 [illegible] 11 [illegible] A [illegible] (**AGM**) [illegible] 2:30 [illegible] 22, 2023 [illegible] 2/ [illegible] 3031 [illegible]

[illegible] A [illegible] 17/ [illegible] 16 [illegible] 24 [illegible] A [illegible]

A, [illegible] 20, 2023

CONTENTS

N[illegible]: [illegible]

DEFINITIONS

[illegible]:

- A [illegible]

[illegible] A, 14, 2023, [illegible]

[illegible] (深圳市樂仁科技有限公司), [illegible] A[illegible] 2, 2007 [illegible]

[illegible]

[illegible]

[illegible] 1.00[illegible] A [illegible]

[illegible]

[illegible] (深圳證券交易所) [illegible]

[illegible] (深圳市天道醫藥有限公司), [illegible] 29, 2004, [illegible]

[illegible] (烏魯木齊水滴石穿股權投資合夥企業（有限合夥）), [illegible] A[illegible] 3, 2007 [illegible]

[illegible]

[illegible]

[illegible] (深圳市多普樂實業發展有限公司), [illegible] 7, 2000 [illegible]

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
（深圳市海普瑞藥業集團股份有限公司）

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

E [illegible] D [illegible]:

[illegible] *(C [illegible] B [illegible])*

[illegible] *(D [illegible] G [illegible] M [illegible])*

[illegible] *(G [illegible] M [illegible])*

I [illegible] D [illegible]:

[illegible]

[illegible]

[illegible]

[illegible] *P C:*

[illegible] 21 [illegible]

[illegible]

[illegible]

P [illegible]

H [illegible] K [illegible]:

[illegible] 4724, 47/[illegible]

[illegible]

30 [illegible]

[illegible]

A[illegible] 20, 2023

[illegible]

[illegible],

2022 WORK REPORT OF THE BOARD OF DIRECTORS
2022 WORK REPORT OF THE SUPERVISORY COMMITTEE
2022 ANNUAL REPORT AND ITS SUMMARY,
H SHARES RESULTS ANNOUNCEMENT,
H SHARES 2022 ANNUAL REPORT,
2022 CORPORATE GOVERNANCE REPORT AND
2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
2022 FINAL FINANCIAL REPORT
2022 PROFIT DISTRIBUTION PROPOSAL
RE-APPOINTMENT OF AUDITORS OF THE COMPANY
ELECTION OF THE SIXTH SESSION OF THE BOARD
REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF THE SIXTH SESSION OF THE BOARD
ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE
PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND CASH FLOW MANAGEMENT USING INTERNAL FUNDS
APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO CERTAIN BANKS FOR 2023
AMENDMENT OF ARTICLES OF ASSOCIATION

1. INTRODUCTION

[illegible]

A. [illegible]:

(1) [illegible] 2022 [illegible]

(2) [illegible] 2022 [illegible]

(3) [illegible] 2022 [illegible] 2022 [illegible] 2022 [illegible] 2022 [illegible]

(4) [illegible] 2022 [illegible]

(5) [illegible] 2022 [illegible]

(6) [illegible]

(7) [illegible]

(8) [illegible]

(9) [illegible]

A. [illegible]:

(10) [illegible]

(11) [illegible] 2023

(12) [illegible]

2. MATTERS TO BE CONSIDERED AT THE ANNUAL GENERAL MEETING

i. 2022 Work Report of the Board of Directors

[illegible] 2022 [illegible]

[illegible] 29, 2023 [illegible]

ii. 2022 Work Report of the Supervisory Committee

[illegible] 2022 [illegible] 29, 2023.

[illegible] 29, 2023 [illegible]

iii. 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report

[illegible] 2022 A [illegible]

[illegible] A [illegible] 2022 A [illegible] 2022 [illegible] 2022 [illegible]

[illegible] 29, 2023 [illegible]

iv. 2022 Final Financial Report

[illegible] 2022 [illegible] 29, 2023.

[illegible] 29, 2023 [illegible]

v. 2022 Profit Distribution Proposal

[illegible] 1 ([illegible]) [illegible] 31, 2022 ([illegible] **Final Dividend**).

[illegible] 29, 2023 [illegible]

[illegible] 2022 [illegible] A [illegible] 15, 2023 [illegible] 31, 2023. [illegible] A [illegible]

vi. Re-appointment of auditors of the Company

[illegible] 2023 [illegible] 2023.

[illegible] 29, 2023 [illegible]

vii. Election of the sixth session of the Board

[illegible] A [illegible] 139 [illegible] A [illegible] 29, 2023 [illegible] (**Mr. Li**), [illegible] (**Ms. Li**) [illegible] (**Mr. Shan**) [illegible] (**Dr. Lu**) [illegible] 29, 2023 [illegible] (**Mr. Zhang**) [illegible] (**Mr. Huang**) [illegible] (**Mr. Yi**) [illegible]

[illegible]

[illegible] 3.4 A [illegible] 14 [illegible]

[illegible]

A [illegible]

viii. Remuneration of independent non-executive Directors of the sixth session of the Board

[illegible] 100,000 [illegible]

ix. Election of the sixth session of the Supervisory Committee

[illegible] A [illegible] 184 [illegible] A [illegible] A [illegible] **Mr. Zheng** [illegible] **Ms. Tang** [illegible]

[illegible]:

[illegible] (鄭澤輝), [illegible] 53, [illegible] 2006. [illegible] 1992 [illegible] 2011.

[illegible]:

[illegible] (唐海均), [illegible] 44, [illegible] 2001 [illegible] 2007. [illegible] 2014.

[illegible]

[illegible] 13.51(2)([illegible]) [illegible] 13.51(2)([illegible]) [illegible]

[illegible]

[illegible]

x. Purchase of Wealth Management Products and Cash Flow Management Using Internal Funds

[illegible] 29, 2023.

[illegible] 29, 2023 [illegible]

xi. Application for Credit Line and Providing Guarantee to Certain Banks for 2023

[illegible] 2023 [illegible] 29, 2023.

[illegible] 29, 2023 [illegible]

xii. Amendment of Articles of Association

[illegible] 29, 2023. [illegible]

[illegible]

3. ANNUAL GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS OF H SHARES

[illegible]

[illegible]

[illegible] 17, 2023 [illegible] 22, 2023 ([illegible]), [illegible] 17, 2023, [illegible] 16, [illegible] 24 [illegible] A [illegible]

[illegible] 17, 2023 [illegible] 22, 2023 ([illegible]), [illegible] 17, 2023, [illegible] 16, [illegible] 4:30 [illegible] 16, 2023. [illegible] 22, 2023 [illegible] A [illegible]

[illegible] 29, 2023 [illegible] 31, 2023, [illegible] 17, 2023, [illegible] 16, [illegible] 4:30 [illegible] 25, 2023. [illegible] 31, 2023 [illegible] 2022 [illegible] A [illegible]

4. VOTING BY POLL

[illegible] 13.39(4) [illegible] A [illegible]

[illegible] A [illegible] A [illegible] A [illegible] ( ) [illegible] ( ). [illegible] A [illegible] 20 [illegible] 24 [illegible]

5. RECOMMENDATION

[illegible]

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
C[illegible]

[illegible]

Non-independent Directors

(i) Mr. Li Li

[illegible] (李鋰), [illegible] 59, [illegible] 28 [illegible] 2012 [illegible]

(ii) Ms. Li Tan

(李坦), 58, [illegible] 28 [illegible]

[illegible] 1998. [illegible] 2007; [illegible] 2007; [illegible] 2014; [illegible] 2010; [illegible] 2013; [illegible] 2015; [illegible] 2016.

[illegible] 1987 [illegible] 2005.

[illegible] 922,391,179 [illegible] 73.96% [illegible] 408,041,280 [illegible] 99.00% [illegible] 1.00% [illegible]); ( ) 474,029,899 [illegible] 99.00% [illegible] 1.00% [illegible]); ( ) 40,320,000 [illegible]).

(iii) Mr. Shan Yu

(單宇), [illegible] 62, [illegible] 28 [illegible]

[illegible] A, 1998. [illegible] 2000; [illegible] 2007; [illegible] 2009; [illegible] 2009; [illegible] 2010; [illegible] 2013; [illegible] A [illegible] A, 2014.

[illegible] 1982 [illegible] 2005.

A [illegible] 99% [illegible] 46,425,600 A [illegible] 38.88% [illegible] 15,118,035 A [illegible] 52,302,892 A [illegible] 3.56% [illegible]

(iv) Mr. Zhang Ping

(張平), [illegible] 58, [illegible] 1992 [illegible] 1998, [illegible]

[illegible] 30 [illegible] 2021 [illegible] A, 2022. [illegible] A [illegible] 2002 [illegible] 2021 [illegible] 1988 [illegible] 2002.

[illegible] A [illegible] A [illegible] A [illegible]

A [illegible]

[illegible] 571 [illegible]), [illegible]

A [illegible] 13.51(2)([illegible]) [illegible] 13.51(2)([illegible]) [illegible]

Independent Non-Executive Directors

(v) Dr. Lu Chuan

[illegible] (呂川), [illegible] 53, [illegible] 2019. [illegible] 2019.

[illegible] 1991 [illegible] 1994. [illegible] 1997 [illegible] 2005, [illegible] 2005 [illegible] 2018, [illegible] (A [illegible] : 300052) A, 2008 [illegible] A, 2012, [illegible] : 8128) [illegible] 2008 [illegible] 2009, [illegible] : 1733) [illegible] 2010 [illegible] 2016, [illegible] 2011 [illegible] 2014.

[illegible]

[illegible]

(vi) Mr. Huang Peng

[illegible] (黃鵬), [illegible] 74, [illegible] 1949, [illegible] 2003. [illegible] 1995 [illegible] 1985. [illegible] 1988, [illegible] (新時代企業家研究院) [illegible] (: 601890), [illegible] (: 301180), [illegible] (: 300819) [illegible] & [illegible] (: 603828). [illegible]

[illegible]

[illegible]

(vii) Mr. Yi Ming

[illegible] (易銘), [illegible] 46, [illegible] 1977, [illegible] 2002 [illegible] 2014. [illegible] 2003 [illegible] 2012. [illegible] 2013 [illegible] 2018. [illegible] 2018 [illegible]

[illegible]

[illegible]

[illegible] 571 [illegible]).

A [illegible] 13.51(2)([illegible]) [illegible] 13.51(2)([illegible]) [illegible]

[illegible]

Existing Provisions of the Articles of Association	Proposed Amendments to the Articles of Association
Article 14 [illegible]	**Article 14** [illegible]
Article 97 [illegible]	**Article 97** [illegible]

Existing Provisions of the Articles of Association	Proposed Amendments to the Articles of Association
[illegible]	[illegible]
Article 150 [illegible]	**Article 150** [illegible]
Article 156 [illegible]	**Article 156** [illegible]
Article 158 [illegible]	**Article 158** [illegible]

NOTICE OF THE 2022 A

NOTICE IS HEREBY GIVEN 2022 Company 22, 2023 2/ 2 02 20 3

ORDINARY RESOLUTIONS

1. 2022
2. 2022
3. A 2022 A
4. 2022
5. 2022

SPECIAL RESOLUTIONS

6.
7. 2023

深圳市

ORDINARY RESOLUTION

[illegible]

8. [illegible];

SPECIAL RESOLUTION

[illegible]

9. [illegible];

ORDINARY RESOLUTIONS

[illegible]

10. [illegible];

[illegible]

11. [illegible]:

11.01 [illegible];

11.02 [illegible];

11.03 [illegible];

11.04 [illegible].

12. [illegible]

12.01 [illegible];

12.02 [illegible];

12.03 [illegible].

13. [illegible]

13.01 [illegible];

13.02 [illegible].

[illegible]

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
C[illegible]

[illegible],
A[illegible] 20, 2023

N[illegible] :

1. [illegible] 17, 2023 [illegible] 22, 2023 ([illegible]), [illegible] 17/[illegible], 16[illegible] 4:30, [illegible] 16, 2023 [illegible].

   [illegible] 22, 2023 [illegible].

2. [illegible].

3. [illegible].

4. [illegible] 17/[illegible], 16[illegible] 24, [illegible].

5. [illegible].

6. [illegible].

7. [illegible].

8. [illegible] 11, 13, [illegible] ( ). [illegible] ( ). [illegible] ( ). [illegible] ( ). [illegible] ( ). [illegible] :

   ( ) [illegible] ( ) [illegible] ( ). [illegible] ( ). [illegible] ( ). [illegible] ;

   ( ) [illegible] ;

( ) [illegible]

9. [illegible]